Research programme: retinal disorder therapeutics - Kodiak Sciences

Drug Profile

Research programme: retinal disorder therapeutics - Kodiak Sciences

Alternative Names: KSI 201; KSI 301; KSI 401

Latest Information Update: 20 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oligasis
  • Developer Kodiak Sciences; Oligasis
  • Class Immunoconjugates
  • Mechanism of Action Angiogenesis inhibitors; Angiotensinogen modulators; Complement system protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Diabetic retinopathy; Dry age-related macular degeneration; Wet age-related macular degeneration

Most Recent Events

  • 20 Sep 2016 Early research in Diabetic retinopathy in USA (unspecified route) (Kodiak Sciences pipeline, September 2016)
  • 10 Nov 2014 Early research in Wet-age-related macular degeneration and Dry age-related macular degeneration in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top